# A Study of QLS5133 Monotherapy in Advanced Solid Tumors

> **NCT07061639** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 212 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QLS5133

## Key facts

- **NCT ID:** NCT07061639
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-07
- **Final completion:** 2028-04
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061639, "A Study of QLS5133 Monotherapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07061639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*